Physics of going viral: Rate of DNA transfer from viruses to bacteria measured

ScienceDaily (June 27, 2012) Researchers at the California Institute of Technology (Caltech) have been able, for the first time, to watch viruses infecting individual bacteria by transferring their DNA, and to measure the rate at which that transfer occurs. Shedding light on the early stages of infection by this type of virus -- a bacteriophage -- the scientists have determined that it is the cells targeted for infection, rather than the amount of genetic material within the viruses themselves, that dictate how quickly the bacteriophage's DNA is transferred.

"The beauty of our experiment is we were able to watch individual viruses infecting individual bacteria,"says Rob Phillips, the Fred and Nancy Morris Professor of Biophysics and Biology at Caltech and the principal investigator on the new study. "Other studies of the rate of infection have involved bulk measurements. With our methods, you can actually watch as a virus shoots out its DNA."

The new methods and results are described in a paper titled "A Single-Molecule Hershey-Chase Experiment," which will appear in the July 24 issue of the journal Current Biology and currently appears online. The lead authors of that paper, David Van Valen and David Wu, completed the work while graduate students in Phillips's group.

In the well-known 1952 Hershey-Chase experiment, Alfred Hershey and Martha Chase of the Carnegie Institution of Washington in Cold Spring Harbor convincingly confirmed earlier claims that DNA -- and not protein -- was the genetic material in cells. To prove this, the researchers used bacteriophages, which are able to infect bacteria using heads of tightly bundled DNA coated in a protein shell. Hershey and Chase radiolabeled sulfur, contained in the protein shell but not in the DNA, and phosphorus, found in the DNA but not in the protein shell. Then they let the bacteriophages infect the bacterial cells. When they isolated the cells and analyzed their contents, they found that only the radioactive phosphorus had made its way into the bacteria, proving that DNA is indeed the genetic material. The results also showed that, unlike the viruses that infect humans, bacteriophages transmit only their genetic information into their bacterial targets, leaving their "bodies" behind.

"This led, right from the get-go, to people wondering about the mechanism -- about how the DNA gets out of the virus and into the infected cell," Phillips says. Several hypotheses have focused on the fact that the DNA in the virus is under a tremendous amount of pressure. Indeed, previous work has shown that the genetic material is under more pressure within its protein shell than champagne experiences in a corked bottle. After all, as Phillips says, "There are 16 microns [16,000 nanometers] of DNA in a tiny 50-nanometer-sized shell. It's like taking 500 meters of cable from the Golden Gate Bridge and putting it in the back of a FedEx truck."

Phillips's group wanted to find out whether that pressure plays a dominant role in transferring the DNA. Instead, he says, "What we discovered is that the thing that mattered most was not the pressure in the bacteriophage, but how much DNA was in the bacterial cell."

The researchers used a fluorescent dye to stain the DNA of two mutants of a bacteriophage known as lambda bacteriophage -- one with a short genome and one with a longer genome -- while that DNA was still inside the phage. Using a fluorescence microscope, they traced the glowing dye to see when and over what time period the viral DNA transferred from each phage into an E. coli bacterium. The mean ejection time was about five minutes, though that time varied considerably.

This was markedly different from what the group had seen previously when they ran a similar experiment in a test tube. In that earlier setup, they had essentially tricked the bacteriophages into ejecting their DNA into solution -- a task that the phages completed in less than 10 seconds. In that case, once the phage with the longer genome had released enough DNA to make what remained inside the phage equal in length to the shorter genome, the two phages ejected DNA at the same rate. Therefore, Phillips's team reasoned, it was the amount of DNA in the phage that determined how quickly the DNA was transferred.

But Phillips says, "What was true in the test tube is not true in the cell." E. coli cells contain roughly 3 million proteins within a box that is roughly one micron (1,000 nanometers) on each side. Less than 10 nanometers separate each protein from its neighbors. "There's no room for anything else," Phillips says. "These cells are really crowded."

And so, when the bacteriophages try to inject their DNA into the cells, the factor that limits the rate of transfer is how jam-packed those cells are. "In this case," Phillips says, "it had more to do with the recipient, and less to do with the pressure that had built up inside the phage."

See the original post:
Physics of going viral: Rate of DNA transfer from viruses to bacteria measured

Posted in DNA

MIT names head of biology dept. as new provost

MIT has named a new provost. The former head of MITs Dept. of Biology, professor Chris Kaiser, will take on the role as provost, replacing MITs President-elect Rafael Reif, the institute announced today.

Kaiser, who has been a cell biologist and professor of biology, has been at MIT since 1991. The professor, 55, chaired the Dept. of Biology from 2004 until earlier this year.

As someone who grew up at MIT first as a graduate student and then as a member of the biology faculty I am extremely grateful to President-elect Reif for giving me the opportunity to serve the Institute in this capacity, Kaiser said in a statement. At MIT, innovation is the norm, and as provost I plan not only to build upon our already-strong programs, but also to continue to foster inventive new directions in education and research.

Kaiser was selected by Reif, the outgoing provost, who will take on his role as president on July 2. Reif selected Kaiser after consulting faculty members and students, according to MIT. The selection was then was confirmed by a vote of the Executive Committee of the MIT Corporation.

In his new role as provost, Kaiser will be responsible for the Institutes educational programs, as well as for the recruitment, promotion and tenuring of faculty. Kaiser will also work with the deans of MITs five schools to establish priorities and will work with the vice president for research and associate provost regarding research priorities.

As the head of the Dept. of Biology, Kaiser managed 14 new junior faculty in the department and in affiliated research institutions including the Whitehead Institute for Biomedical Research, the Koch Institute for Integrated Cancer Research, and the Broad Institute.

His efforts in genetic, biochemical and structural biology research methods have led to the identification of numerous genes and mutations involved in these processes.

More:
MIT names head of biology dept. as new provost

Oligonucleotide Delivery: Biology, Engineering and Development Conference

Public release date: 27-Jun-2012 [ | E-mail | Share ]

Contact: Kevin Korpics kevin@engconfintl.org Engineering Conferences International

Oligonucleotide technologies, such as siRNA, tap into endogenous, highly conserved and specific catalytic mechanisms to efficiently regulate gene expression. As such, they have the potential to enable the development of novel therapeutic options for disease targets previously considered un-druggable by conventional small molecule and biologics means. However, despite the promise, clinical development has been hindered by the challenges encountered by identifying and developing safe and efficacious delivery formulations.

Since its discovery in 1998, RNA silencing has attracted much attention, with over 50,000 peer-reviewed publications, multiple national and international conferences, and significant investment in the biotech and large pharma with the goal of developing new siRNA-based therapies. Despite the interest and investment this has proven to be more difficult that first envisioned. It is widely recognized that there are gaps in our basic understanding on how to best harness this technology for therapeutic use.

The major topics to be discussed are:

Liposomes, nanosomes, polymeric and nano-particulate delivery vehicles RNA chemical modifications and conjugates to enable delivery Protein transduction domain as delivery platforms Mechanisms of cellular uptake and endosomal escape Biophysical characterization methods siRNA delivery vehicle toxicology Local and systemic siRNA delivery case studies

Confirmed Speakers Achim Aigner, Philipps-University Marburg, Germany Saghir Akhtar, Kuwait University, Kuwait Eben Alsberg, Case Western Reserve University, USA Dan Anderson, MIT, USA Tomohiro Asai, University of Shizuoka, Japan Himanshu Brahmbhatt, EnGeneIC Ltd, Australia Bob Brown, Dicerna, USA Kenneth Clark, GlaxoSmithKline, UK Pieter Cullis, University of British Columbia, Canada Mark E. Davis, California Institute of Technology, USA Derek M. Dykxhoorm, University of Miami Miller School of Medicine, USA Xavier de Mollerat Du Jeu, Life Technologies, USA Omid Farokhzad, Harvard Medical School, USA Elena Feinstein, Quark Pharma, Israel / USA Mauro Ferrari, The Methodist Hospital Research Institute, USA Mercedes Gonzlez-Juarrero, Colorado State University, USA Tatsuhiro Ishida, The University of Tokushima, Japan Rudy Juliano, University of North Carolina Chapel Hill, USA Jan Kamps, University of Groningen, The Netherlands Kazunori Kataoka, University of Tokyo, Japan Jrgen Kjems, rhus University, Denmark Troels Koch, Santaris Pharma A/S, Denmark / USA lo Langel, Stockholm University, Sweden Gabriel Lpez-Berestein, The University of Texas MD Anderson Cancer Center, USA Zheng-Rong Lu, Case Western Reserve University, USA Jennifer MacDiarmid, EnGeneIC Ltd, Australia Ram I. Mahato, University of Tennessee Health Science Center, USA Muthiah Manoharan, Alnylam Pharmaceuticals, USA Nigel A.J. McMillan, Diamantina Institute, University of Queensland, Australia X in Ming, University of North Carolina Chapel Hill, USA Tamara Minko, Rutgers University, USA Andrs Montefeltro, nLife Therapeutics, Spain Sterghios Moschos, University of Westminster, UK Deborah Palliser, Albert Einstein School of Medicine, USA Dan Peer, Tel Aviv University, Israel Jean Phillipe Pellois, Texas A&M University, USA Blake Peterson, The University of Kansas, USA Tariq M. Rana, Sanford-Burnham Medical Research Institute, USA Steven L. Regen, Lehigh University, USA John Rossi, City of Hope, Duarte, USA Dmitry Samarsky, RiboBio, China Ansgar Santel, Silence Therapeutics AG, Germany Alan D. Schreiber, ZaBeCor Pharmaceuticals, Inc., USA Sabine Schreidler, Sanofi-Aventis, Germany Georg Sczakiel, University of Lbeck, Germany Peter H. Seeberger, Max Planck Institute of Colloids and Interfaces, Berlin, Germany Rita Serda, Methodist Hospital Research Institute, USA Mouldy Sioud, Norwegian Radium Hospital, Norway Anil Sood, MD Anderson Cancer Center, USA Janos Szebeni, Semmelweis University, Budapest, Hungary C. Shad Thaxton, Northwestern University, USA Ernst Wagner, Ludwig-Maximilians-Universitat, Munchen, Germany Roberto Weinmann, Sylentis, Spain Johannes Winkler, University of Vienna, Austria You-Yeon Won, Purdue University, USA Matthew Wood, Oxford University, UK Miqin Zhang, University of Washington, USA

###

Submission of Abstracts

ABSTRACT SUBMISSION IS NOW OPEN

The rest is here:
Oligonucleotide Delivery: Biology, Engineering and Development Conference

MIT taps Chris Kaiser, former head of biology department, as new provost

By Sarah N. Mattero, Globe Correspondent

Chris A. Kaiser, professor and former chairman of the Department of Biology at MIT, has been named the colleges new provost.

Kaiser succeeds L. Rafael Reif, who recently was appointed MITs president. Reif and Kaiser will assume the positions of president and provost, respectively, on July 2.

Kaiser, 55, of Concord, has been a member of faculty since 1991. He served as the biology department chairman from 2004 until earlier this year.

A distinguished scholar and a master teacher in his field, he has also played a key role on a number of Institute-wide committees, advancing the broader mission of MIT with curiosity, creativity, empathy and a marvelous sense of humor, Reif said of Kaiser in a statement. I have no doubt that he will thrive as provost.

The provost is MITs senior academic and budget officer who also oversees the recruitment and promotion of faculty with overall responsibility for the schools educational programs.

See more here:
MIT taps Chris Kaiser, former head of biology department, as new provost

Research and Markets: Dictionary of Developmental Biology and Embryology, 2nd Edition

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/76ggj5/dictionary_of_deve) has announced the addition of John Wiley and Sons Ltd's new book "Dictionary of Developmental Biology and Embryology, 2nd Edition" to their offering.

A newly-revised edition of the standard reference for the field today updated with new terms, major discoveries, significant scientists, and illustrations

Developmental biology is the study of the mechanisms of development, differentiation, and growth in animals and plants at the molecular, cellular, and genetic levels. The discipline has gained prominence in part due to new interdisciplinary approaches and advances in technology, which have led to the rapid emergence of new concepts and words. The Dictionary of Developmental Biology and Embryology, Second Edition is the first comprehensive reference focused on the field's terms, research, history, and people.

This authoritative A-to-Z resource covers classical morphological and cytological terms along with those from modern genetics and molecular biology. Extensively cross-referenced, the Dictionary includes definitions of terms, explanations of concepts, and biographies of historical figures. Comparative aspects are described in order to provide a sense of the evolution of structures, and topics range from fundamental terminology, germ layers, and induction to RNAi, evo-devo, stem cell differentiation, and more. Readers will find such features of embryology and developmental biology as:

- Vertebrates

- Invertebrates

- Plants

- Developmental genetics

- Evolutionary developmental biology

Visit link:
Research and Markets: Dictionary of Developmental Biology and Embryology, 2nd Edition

Healthscope to commercially launch Circadian’s Cancers of Unknown Primary Diagnostic Test

MELBOURNE, Australia, June 26, 2012 /PRNewswire/ --Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that it has been advised by its development partner, Healthscope Advanced Pathology, that it will commercially launch Circadian's novel technology for aid in the diagnosis of "Cancers of Unknown Primary" (CUP), on Monday July 16 2012 in Australia, New Zealand, Singapore and Malaysia under the brand CUPGUIDE.

The diagnostic test method has been developed in collaboration between Circadian, Healthscope, the Peter MacCallum Cancer Centre, a leading specialty cancer centre, and scientists at NICTA, Australia's Information and Communications Technology (ICT) Research Centre of Excellence.

A publication in March 2012 from Healthscope reported that the CUP test was able to detect actual primary source of tumour type with 93% accuracy within the first three predictions and had 98.5% specificity across 15 different tumour types.

Healthscope, through its subsidiary Clinical Laboratories Pty Ltd, has rights to develop, clinically validate and market the test throughout Australia, New Zealand, Malaysia and Singapore. Circadian retains rights to market the test in the remainder of the world. Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the test. Circadian, through its wholly owned subsidiary Cancer Therapeutics Limited, owns exclusive worldwide rights to the test through a licensing arrangement with the Peter MacCallum Cancer Centre and NICTA.

The CUP diagnostic methodology identifies a patient's tumour type by comparing its pattern of gene expression to a database of known tumours. It is hoped that by correctly identifying a patient's tumour type, clinicians can choose the most effective treatment strategy for the cancer. CUP is generally less well known and publicised than other cancer types. However, it is actually more common than leukaemia and is the fifth most common cause of death due to cancer in Australia. In 2007, Cancer Council Australia estimated the incidence of CUP to be around 2900 case per annum; American Cancer Society estimated USA incidence at around 32,000 per annum and Cancer Research UK estimated UK incidence at 14,000 per annum.

Robert Klupacs, Circadian Managing Director and CEO stated, "We are absolutely delighted that after all of the efforts of the collaborative partners that CUPGUIDE will now be available to oncologists and pathologists. We are extremely hopeful that CUPGUIDE will have a major impact in significantly improving the clinical diagnosis of CUP."

Dr Keith Byron, Scientific Director of Healthscope's Advanced Pathology Division said, "Healthscope is proud and excited that after the extensive development program we have undertaken with our partners that we will now be able to provide this ground breaking diagnostic technology on a commercial basis. The test is an important addition to our existing business of providing diagnostic tools for doctors throughout our 43 hospitals and the health care industry in general."

Prof David Bowtell, Head of the Cancer Genomics Program at the Peter MacCallum Cancer Centre and a co-inventor of the diagnostic methodology added, "The approach was initially developed in our lab several years ago but the assay needed to be made more generally available. Circadian and Healthscope have been critical to taking the work forward and it is very gratifying that this product of our translational research efforts will be made available to clinicians throughout the region. The concept of personalising treatments for patients based on highly specialised diagnostics is now very well accepted in oncology and has been shown to have significant patient benefit. We believe that the assay will lead to earlier diagnosis, improved treatment outcomes and enhanced quality of life for patients."

Dr Adam Kowalczyk, Leader of Diagnostic Genomics Team in NICTA's Victorian Research Laboratory, and a co-inventor of the diagnostic methodology added, "It is very satisfying that formal techniques for signal detection and pattern recognition can be utilised in practical medical applications. This diagnostic test heralds imminent arrival of many new developments bringing promises of personalised medicine and genomics, in particular, to everyday usage that benefits patients."

Company enquiries

Read the original post:
Healthscope to commercially launch Circadian's Cancers of Unknown Primary Diagnostic Test

PRACTICAL NUTRITION: Watch your drinks, as well as your food

Did you hear about the woman in New Zealand who died from drinking too many sodas? Turns out she drank more than 2 gallons of Coca-Cola and smoked at least 30 cigarettes daily. She also ate very little food.

Any extreme habits or addictions can be dangerous, so soda only played a part in her death. However, sodas aren't completely innocent.

According to the 2010 Dietary Guidelines, 16 percent of our total calories come from added sugars. Of that amount, 46 percent come from sodas, energy drinks, sports drinks and sugar-sweetened juice drinks.

Many people are totally unaware of the number of calories they drink. Often people come to me for weight-loss counseling, and they drink 800 to 1,000 soda calories daily. They won't lose weight until they cut back or cut out those calories and make better food choices.

Some people switch to diet sodas, which does cut calories. However, both regular and diet sodas can contain caffeine, which is problematic for some individuals. Also the phosphorus in all sodas increases calcium loss, which raises osteoporosis risk, if consumed in large amounts.

Others add water to soda or juice to save calories. Adding water increases the volume and dilutes the beverage, but those calories don't magically disappear.

Often people trade sodas for juice. They exchange the caffeine, phosphorus and calories in soda for the vitamins, minerals and calories of juice. Twelve ounces of Fanta Orange soda has 160 calories; 12 ounces of orange juice has 165.

Gatorade and other electrolyte replacement drinks don't seem so sweet, but 12 ounces provide 75 calories. Energy drinks are higher in calories for 12 ounces: Amp, 165, and Red Bull, 160.

Milk is a good source of vitamin D, calcium and protein. To protect your bones, aim for 8 ounces, three times daily. That amount of skim milk provides 258 calories. But 16-ounce portions three times daily would double it to 516 calories. So watch portions of even healthy beverages.

The Institute of Medicine states that the average healthy adult male needs 13 cups of fluid daily, just more than 3 quarts. Women need 9 cups or about 1 quarts. While we get some fluid from our food, water is a simple and natural way to help meet that need.

The rest is here:
PRACTICAL NUTRITION: Watch your drinks, as well as your food

Nutrition, finances win with healthful school snacks, report says

The federal government is slated to come up with rules governing the food sold at school thats not part of the regular meals.

Those foods are often called competitive foods, because whats sold in the student store or in vending machines or other spots at schools often competes with the meal programs.

Ensuring that schools sell nutritious foods is critical to improving childrens diets, a report issued Tuesday says. This is one of the goals of the Healthy, Hunger-Free Kids Act.

That law, passed in 2010, directs the federal government to update standards for all foods sold at school by bringing them into alignment with dietary guidelines.

An assessment of what those new rules might do for kids health and the schools bottom line was released Tuesday by two projects from the Pew Charitable Trusts and the Robert Wood Johnson Foundation.

The projects argue for standards that require competitive foods and beverages to be healthy. Many districts have implemented standards already: In Los Angeles, for example, no soda can be sold and there are fat, salt and sugar standards for snack foods sold at schools.

The federal standards to come from the Department of Agriculture would be the minimum required, and some districts already have high standards, says Jessica Donze Black, director of one of the projects, the Kids Safe & Healthful Foods Project.

Theres frequent complaining that kids wont eat healthful food at school, but Black says thats not so. Given the choice between carrots and chips, they might choose the chips, but if the choice is carrots or celery, kids will eat.

If they have fewer unhealthy options, they are far more likely to choose heathier school lunch options, she said in a telephone interview Monday.

She also says that school districts can help get kids interested in healthful food with taste tests, free samples and other marketing tricks.

The rest is here:
Nutrition, finances win with healthful school snacks, report says

Caraviello: Kenseth's impact goes beyond wins, longevity

This one is going to take some getting used to.

Matt Kenseth's first start at NASCAR's highest level was in 1998 at Dover, where he drove a No. 98 car in relief of Bill Elliott, whose father had passed away. The sixth-place effort turned in by the Wisconsin native that Sunday ranked as the best debut by a Cup newcomer since Rusty Wallace had finished second in Atlanta 18 years earlier. In every event that Kenseth has run since in what is now Sprint Cup, all 451 of them entering Saturday night's race at Kentucky Speedway, he has been behind the wheel of the No. 17.

It's as much a part of him as his steady driving style or his dry sense of humor, and it's going to be very odd seeing him drive anything else -- although that will be the case next season, given the news Tuesday that the 2003 champion and two-time Daytona 500 winner will part ways with Roush Fenway Racing at the end of the year. Nationwide Series champion Ricky Stenhouse Jr., as much a star in the making as Kenseth was in that first race at Dover all those years ago, will step into the No. 17 next season, and his predecessor will move on to a new organization that's yet to be determined.

This isn't a total shock. For some time now, Roush Fenway has had too many good drivers and not enough cars and sponsors, and the team needed to do something to ensure that Stenhouse would stay in the fold. Kenseth is in a contract year, and even for him, he's been exceedingly tight-lipped when asked about his status. His sponsorship situation was patchwork at best, forcing Roush Fenway to occasionally fund the car on its own. There are other drivers out there in the final years of their contracts, and cars with sponsorship that would be available should teams decide to take action. Kenseth, who would be an upgrade almost anywhere he goes, wrote on Twitter that he has nothing yet to announce for 2013. But it's difficult to believe a driver as smart as he is would make such a move without a plan.

Regardless, it's going to be very strange to see Kenseth paired with another car number, given how much personal investment he's poured into the No. 17. No, he hasn't been synonymous with any certain sponsor, and he hasn't worn the same color firesuit for his entire stint with owner Jack Roush. But other than Mark Martin, who put Roush's team on the map and gave it year-in, year-out credibility, there's been no more important driver to the organization. It was Kenseth who brought Roush his first premier-series championship after years of painfully close calls, and six years later he delivered the team's first victory in the Daytona 500.

"It's the end of an incredible run between Jack and Matt, one that has spanned 15 years, which in his day and age of professional sports is much longer than you'd expect," said Roush Fenway president Steve Newmark. "So we're proud of everything that's been accomplished there."

But it all goes much deeper than the time span. Even after Kenseth leaves, his fingerprints will be all over his former organization. Robbie Reiser, the Roush Fenway general manager often credited with helping to build the team into the three-headed monster it is now, came up with Kenseth on the Wisconsin late-model circuit and broke through first as the driver's car owner, and later as a championship-winning crew chief. And then there's Kenseth himself, who often has been given the latitude to mold the No. 17 team as he sees fit, making crew chief changes and maintaining a degree of supervision over that program that not all elite drivers have.

Yes, it's going to be an odd transition, and not just because of the car number -- although if you remember a press release touting a new associate sponsor for this season, one that allegedly entailed a new numeral on the side of Kenseth's vehicle, it did not sit well with the masses. Yes, Tony Stewart left the No. 20. Yes, Dale Earnhardt Jr. walked away from the No. 8. But neither of those drivers were in those cars for as long as Kenseth has been in the No. 17. Stewart may have won a pair of championships in his former ride, but until he became an owner, he couldn't match Kenseth's de facto management role. Earnhardt had the level of personal investment at Dale Earnhardt Inc. but couldn't match his friend's results on the race track.

Kenseth did it all. He didn't just drive the No. 17; when times were tough, he bled over it. Roush might have owned the vehicle, but no one held more of a sense of ownership in it than Kenseth. When he faced struggles like those that followed his back-to-back wins at Daytona and Fontana to open the 2009 season, he seemed to take them personally. When it came time to shuffle personnel to try and get things back on track, Kenseth played an active role in shaping the direction of the program. Some crew chief moves -- and there were a few of them back then, until Jimmy Fennig arrived from the research and development department to straighten everything out -- were solely the driver's call.

Surely, Kenseth will bring that same level of involvement to whatever organization becomes his next home. His sudden availability only will tighten the microscope around drivers like Joey Logano and AJ Allmendinger, who are in contract years at Joe Gibbs Racing and Penske Racing, respectively. This isn't Kurt Busch, burning bridges when no others are available. This is a championship-caliber driver with a good reputation and a strong work ethic who would fit in well at a number of places and will absolutely land on his feet.

Go here to read the rest:
Caraviello: Kenseth's impact goes beyond wins, longevity

Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device

ROCHESTER, N.Y., June 26, 2012 /PRNewswire/ --Thermal Gradient, Inc., a developer of disposable ultra-fast DNA testing devices, announced today that it has initiated the manufacture of its next generation device. Robert Juncosa, the company's Chief Technology Officer stated, "Our previous generation device was a huge success. It performs PCR, the critical step in almost all DNA tests, in less than eight minutes. This new device is capable of "real-time" PCR, a process used to determine the amount of initial DNA being tested. This is very important when testing for infectious diseases like HIV."

Because of design improvements over the previous generation, the new device will is expected to perform better but will cost less to manufacture.

"Our recent breakthroughs and this new device position us as the premier technology for both point of care and high throughput clinical laboratory testing," says CEO Joel Grover. "Because of our speed, low cost, and fundamental design, the hardware module required to perform a quantitative DNA test is small. This makes it easily scalable to achieve high throughput systems in a modest instrument footprint."

The company will begin testing the new devices in the third quarter. Dr. Grover added, "When our internal testing is complete, we will then make cartridges and demonstration platforms available to diagnostic systems developers for their evaluation and assay optimization."

About Thermal GradientThermal Gradient develops devices and systems based on its patented technology that enables nucleic acid testing to be performed in minutes instead of an hour or more. Systems based on this technology can be developed for clinics and remote settings as well as for main-line diagnostic platforms for the clinical laboratory. For more information, please visit: http://www.thermalgradient.com

Contact:Joel Grover, Ph.D Chief Executive Officer Thermal Gradient, Inc. 585-248-9598 info@thermalgradient.com

The rest is here:
Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device

Posted in DNA

Research and Markets: DNA Sequencing and PCR Markets

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5f3wk7/dna_sequencing_and) has announced the addition of the "DNA Sequencing and PCR Markets" report to their offering.

DNA sequencing and polymerase chain reaction (PCR) are two major technology platforms of value in life science research, drug discovery and clinical diagnostics. The markets for sequencing are extremely competitive, driven by rapid technological advancements and aggressive price wars. Next-generation sequencing presents an exciting area of growth for life science tool vendors, including those providing sequencers, ancillary instrumentation, reagents and software.

This TriMark Publications report provides an in-depth analysis of key technology and market trends in the high-throughput sequencing space while analyzing the main drivers of growth in markets for PCR products and applications. The study provides a thorough overview of DNA sequencing and PCR, including applications, opportunities, technological trends, and market share and dynamics with a particular focus on the U.S., Japan, European, and Brazil, Russia, India and China (BRIC) markets.

This report also analyzes almost all of the companies known to be marketing, manufacturing or developing DNA sequencing and PCR products in the U.S. and worldwide. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

Key Topics Covered:

1. Overview

2. Introduction to DNA Sequencing and PCR Technology

3. DNA Sequencing Technologies and Market Analysis

4. PCR and DNA Amplification Technologies and Markets

Read more from the original source:
Research and Markets: DNA Sequencing and PCR Markets

Posted in DNA

Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology …

Two Abstracts Selected for Oral Presentation

Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development

CAMBRIDGE, Mass., June 26, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (MACK), a biopharmaceutical company with a pipeline of eight oncology therapeutics and multiple diagnostics, announced today that two oral presentations and three posters on its Network Biology approach to therapeutic development will be presented at the American Association for Cancer Research (AACR) Special Conference "Chemical Systems Biology: Assembling and Interrogating Computational Models of the Cancer Cell by Chemical Perturbations" being held June 27 -- 30, 2012, at the Marriott Copley Place in Boston, Mass.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-looking statements

Any statements in this press release about Merrimack's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Read the rest here:
Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology ...

Loch Ness Monster real in biology textbook

An undated photo of a shadowy shape that some people say is the Loch Ness monster. (AP)

This would be funny if it werent so, well, not funny.

A biology textbook used by a Christian school in Louisiana that will be accepting students with publicly funded vouchers in the fall says that the Loch Ness Monster in Scotland is real. And it isnt just any monster but a dinosaur an effort to debunk evolution and bolster creationist theory.

The story, reported in the Scotsman newspaper in Scotland, says that Eternity Christian Academy in Westlake is one of the many Christian schools in the United States that uses these books published by Accelerated Christian Education.

The Biology 1099 edition includes a passage about the Loch Ness Monster that says, in part, according to the newspaper:

Are dinosaurs alive today? Scientists are becoming more convinced of their existence. Have you heard of the Loch Ness Monster in Scotland? Nessie for short has been recorded on sonar from a small submarine, described by eyewitnesses, and photographed by others. Nessie appears to be a plesiosaur.

Marie Carrier, principal of Eternity Christian Academy, was quoted by the New York Daily News as saying that she would like to accept 135 voucher students for next year to join the 38 children already attending the school in grades 1 through 8.

The reason all of this matters now to the public is that Louisiana Gov. Bobby Jindal recently signed a law that sets up the largest voucher program of any state in the country. Some 125 private and religious schools from across the state are qualified to participate in the Louisiana Believes program, which gives families public money to pay school tuition for their children.

It is interesting to note that one of the schools originally on the list, the Islamic School of Greater New Orleans, withdrew its application for voucher students after an outcry about its participation by some lawmakers.

It seems that fundamentalist Christian schools are acceptable to receive public money, but Islamic schools are not. Republican state Rep. Kenneth Harvard was quoted by the Associated Press that he would not support public funding for Islamic teaching.

See the article here:
Loch Ness Monster real in biology textbook

Grant brings student researchers to Western

This summer, from June 18 through Aug. 24, Western will host 10 students from across the country to participate in the Research Experiences for Undergraduates Program.

Spiegel, who is involved in REU, said this program benefits Westerns community by making the department and university more visible to other institutions and expanding Western's already vibrant research culture. Students need to be exceptional academically, show interest in research in their personal statements and we look for students who wouldnt have this opportunity otherwise, he said.

The main purpose of the REU program is to give students the opportunity to experience authentic research not found anywhere else, according to Westerns chemistry department's website.

Many students involved in the REU are from community colleges and small liberal arts universities, which may not have the funding or facilities to provide this kind of experience, Spiegel said.

REU programs at other institutions around the country work in a broad range of scientific fields, but at Western the focus is on chemistry, according to the chemistry department's website. During the 10-week program, Western provides students with a $4,500 stipend, a $1,000 allowance for meals and a reimbursement on travel expenses.

Nathan Drake, a Western student and biochemistry major, is head of support for the REU program.

Students are able to ask him questions they dont feel as comfortable asking their assigned faculty members, such as the best place to get coffee, supplies for living situations and can utilize him as a tour guide to make the transition easier, Drake said.

Charlie Snyder, an REU participant from Skidmore College in New York, is working with John Gilbertson to find a metal complex that can turn carbon dioxide into carbon monoxide, she said. Snyder said she thinks this the extensive lab experience will build her skills and improve her resume.

Visiting students work either with existing groups or individually, and always with a faculty member as a mentor. The research focuses on the field of synthetic chemistry, biochemistry and materials chemistry, Spiegel said. Being humbled by undergraduates' enthusiasm and raw intelligence are Spiegels favorite parts about working with the students, he said.

Washington benefits from this program because qualified students are better prepared for a high-tech, competitive workforce after graduation. Many program alumni get jobs in the Seattle area, Spiegel said.

Read the original post:
Grant brings student researchers to Western

Exercise is key in the fight against Alzheimer’s disease

Public release date: 27-Jun-2012 [ | E-mail | Share ]

Contact: Angela Hopp ahopp@asbmb.org 240-283-6614 American Society for Biochemistry and Molecular Biology

In a recent Journal of Biological Chemistry "Paper of the Week," research led by Ayae Kinoshita at the Kyoto University Graduate School of Medicine in Japan reveals the benefits of exercise in combating Alzheimer's disease.

The most common cause of dementia, Alzheimer's disease results in the loss of cognitive faculty. In the majority of cases, Alzheimer's disease occurs after age 65, and factors such as diet and exercise appear to play a role in its development, with high-fat diets as a risk factor.

Kinoshita's research compared the effects of 1) diet control, 2) voluntary exercise and 3) diet control plus exercise in an Alzheimer's disease mouse model. The results showed that exercise was more beneficial than diet control in reducing -amyloid formation (a defining characteristic of Alzheimer's disease) and restoring memory loss induced by a high-fat diet in these mice. Moreover, Kinoshita's team found that the effect of diet control plus exercise was not significantly different than exercise alone. They attribute the positive effects of exercise to increased degradation of -amyloid deposits in the brain.

"Based on the results in this research," Kinoshita suggests, "exercise should be given priority to prevent Alzheimer's disease."

From the article: "Exercise is more effective than diet control in preventing high fat diet-induced -amyloid deposition and memory deficit in amyloid precursor protein transgenic mice" by Masato Maesako, Kengo Uemura, Masakazu Kubota, Akira Kuzuya, Kazuki Sasaki, Naoko Hayashida, Megumi Asada-Utsugi, Kiwamu Watanabe, Maiko Uemura, Takeshi Kihara, Ryosuke Takahashi, Shun Shimohama and Ayae Kinoshita

Read the Paper in Press version here: http://www.jbc.org/content/early/2012/05/14/jbc.M111.315358.abstract.

Corresponding author: Ayae Kinoshita, School of Human Health Sciences, Kyoto University Graduate School of Medicine in Kyoto, Japan; email: akinoshita@hs.med.kyoto-u.ac.jp

###

Read the original here:
Exercise is key in the fight against Alzheimer's disease

Would you date a man who wears makeup? Emma Stone says…

The actress weighs in on the booming men's makeup market with TODAY's Professionals, revealing whether she'd date a dude who wears tinted moisturizer.

Makeup for men is one of the hottest trends in the beauty industry. By 2016, the male cosmetics industry for tinted moisturizers, anti-aging creams, concealers, powders will be worth $3.2 billion. But cosmetics for men arent a welcome addition to everyones medicine cabinet.

I dont need much help, proclaimed TODAY's Professionals panelist Donny Deutsch on Tuesday.

Its a turn off for me, responded NBCs chief medical editor Nancy Snyderman.

But "Spiderman" actress Emma Stone was a little more accepting of the trend:

A resounding yes, 100 percent, she told Matt Lauer. You have to wear tinted moisturizer on camera. Weekend wear? I dont know, Ill think about it.

What do you think? Would you date a man who wears cosmetics?

Would you date a guy who uses cosmetics?

More: Beauty products for men? Just dont call it makeup 6 ways Emma Stone lays on the charm Emma Stone eyes fall-back career if acting doesn't pan out

More:
Would you date a man who wears makeup? Emma Stone says...

AP State News Briefs

Add Your Comment | Read (0) Comments

Published 6/26/2012 in News

AP: KU Med gets $1 million for physiology professor

KANSAS CITY, Kan. (AP) The University of Kansas Medical Center will use a $1 million gift to create a physiology professorship.

The university's endowment announced the gift Monday from Jim Osborn of Honolulu.

The gift honors Osborn's daughter, who worked in physiology at the medical center in 1968 and 1969 before dying in a car accident in 1970. At the time of her death, Kathleen Osborn was a junior at the University of Missouri.

Paul Cheney, chairman of the molecular and integrative physiology department, is the first recipient of the Kathleen M. Osborn Chair in Molecular and Integrative Physiology.

Osborn and his wife, Marion, already established the Kathleen Osborn Lectureship at the medical center. And Osborn established the Marion M. Osborn Professorship for Reproductive Science at the Kansas School of Medicine.

AP: Dodge City preparing to welcome disabled riders

DODGE CITY (AP) Dodge City is preparing to welcome 16 physically challenged veterans who are riding bicycles across the country to show people that they aren't defined by those challenges.

See the original post:
AP State News Briefs

A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market

NEW YORK, June 26, 2012 /PRNewswire/ -- A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market

http://www.reportlinker.com/p0920065/A-Product-and-Pipeline-Analysis-of-the-US-Type-2-Diabetes-Mellitus-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This research service presents a marketed and pipeline analysis of the U.S. type 2 diabetes mellitus market. According to the 2011 National Diabetes Fact Sheet, 25.8 million children and adults (or 8.3 percent of the population) in the United States suffer from diabetes. Type 2 diabetes mellitus is the most common form of diabetes; approximately 90 to 95 percent of diabetes patients suffer from type 2 diabetes mellitus. The purpose of this study is to highlight the current market landscape, and provide a competitive analysis of all marketed and pipeline drugs in development for type 2 diabetes mellitus. Dashboard slides are provided for all marketed and Phase 3 drugs in development for type 2 diabetes mellitus.

2. Introduction

Market Overview - Segmentation

3. Competitive Landscape

Type 2 Diabetes Competitive Landscape - Orals

Type 2 Diabetes Competitive Lanscape - Parenterals

Product Analysis - Orals

Product Analysis - Parenterals

Link:
A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market

AccelPath, Inc. Working with Three Pathology Laboratories

GAITHERSBURG, Md.--(BUSINESS WIRE)--

AccelPath, Inc. (ACLP) (AccelPath or the Company) announced today that the Company is working with three pathology laboratories in Texas.

The three pathology laboratories are located near Houston, Texas. Interpretations for these laboratories are provided by the Company's interpretation partner, which has the exclusive rights to interpret all tissue pathology slides processed in these laboratories. In addition, the Company provides consulting services to the laboratories as they transition from non-digital, physical transportation of slides (to the interpretation partner) to eventually complete transmission of both slide and patient information digitally to remote reading site. These laboratories recognize the cost, logistical and other advantages of moving to digital transmission of pathology information and recognize that AccelPath provides the only available practical solution for digital telepathology. These laboratories provide AccelPath with an estimated initial total revenue base of approximately $250,000 per year.

The Company has begun to install and use modules of its proprietary workflow software AccelSlideTM in these laboratories. Eventually, these laboratories will utilize AccelSlideTM fully to digitize the transport of patient records and digital slide images to reading centers anywhere in the United States and internationally. This workflow software continues to develop, improve and expand while being used by these laboratories. Also, they use AccelSlideTM, the laboratories provide valuable user feedback to the Company to further improve the workflow software.

"We believe that there are significant benefits to transitioning to digital pathology for our laboratory practice, stated Dr. RM. After our extensive research into digital telepathology solutions and service providers, we were convinced that AccelPath was the company that had the only viable digital solution. They currently provide us with remote pathology services through a very reputable institutional partner, while we utilize their workflow software solution to transition our practice to become fully digital. Our experience with the Company has been exemplary and we look forward to continuing our relationship.

We are very pleased with our commercial and collaborative relationship with these three pathology laboratories, stated Shekhar Wadekar, AccelPaths Chairman and Chief Executive Officer. It is important to have customers who provide exclusive rights to their pathology, while assisting us improve AccelSlideTM with real-time feedback on our workflow software in addition to generating current revenues for the Company. We plan on expanding our product offerings in this region while we also continue to discuss other regional relationships both in the US and abroad.

About AccelPath

AccelPath provides technology solutions that play a key role in delivering information required for diagnosis of diseases and other pathologic conditions with and through its associated institutional pathologists. The medical institutions, with whom the Company partners, prepare comprehensive diagnostic reports of a patients condition and consult with referring physicians to help determine the most appropriate treatment. Such diagnostic reports enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients health in a cost-effective manner. The Company seeks out referring physicians and histology laboratories in need of high-quality pathology interpretations and manages HIPAA-compliant digital case delivery and reporting while developing comprehensive solutions for managing medical information.

AccelPath is currently focused on the $14 billion anatomic pathology market in the US. The Companys business model builds upon the expertise of experienced pathologists to provide seamless, reliable and comprehensive pathology and special test offerings to referring physicians using conventional and digital technologies. The Company establishes longstanding relationships with the referring physicians as a result of focused delivery of its partners diagnostic services, personalized responses and frequent consultations, and its proprietary flexible information technology, or IT, solutions that are customizable to the referring physicians or laboratories as well as the pathologists needs. Such diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients health in a cost-effective manner. AccelPaths IT and communications platform enables it to efficiently and securely deliver diagnostic reports to referring physicians. In addition, AccelPaths IT platform enables close tracking and monitoring of medical statistics.

AccelPath is focused on the design, research, development and integration of three-dimensional imaging devices and systems primarily in the healthcare industries which it contributes to the Company. The Company will also exploit its three-dimensional imaging technology for use in intelligent surveillance devices and systems, as well as three-dimensional facial recognition systems for security and law enforcement agencies through future strategic partnerships. Historically, the Companys largest customers have been the National Institutes of Health and the Department of Defense.

Read the original here:
AccelPath, Inc. Working with Three Pathology Laboratories

Abbott Introduces New Limited Ingredient Nutrition Bar – Perfectly Simpleâ„¢ by ZonePerfect®

ABBOTT PARK, Ill., June 26, 2012 /PRNewswire/ -- Abbott's ZonePerfect brand introduces a new line of nutrition bars, Perfectly Simple. With 10 or fewer ingredients and an excellent source of protein, the bars are free of gluten, preservatives and added coloring.

Perfectly Simple by ZonePerfect is a bar built by consumers. In market research activities, consumers were given more than 50 ingredients and asked to construct their ideal nutrition bar that included 10 grams of protein, flavors they enjoy and limited ingredients. Perfectly Simple is the result.

Perfectly Simple by ZonePerfect is available in Peanut Crunch, Cranberry Almond and Toasted Coconut flavors.

To celebrate the launch, ZonePerfect is sampling the new bars in early July via its web site at zoneperfect.com, while supplies last.

News Facts:

Commentary on Perfectly Simple by ZonePerfect:

Heather Bauer, RD, CDN; CEO, NuTrain:

"As a nutritionist who coaches everyone from top CEOs to celebrities and fellow moms, I always see the same thing: everyone wants a healthy lifestyle that is sustainable for life. Delicious nutrition is essential for on-the-go consumers. Whether fueling your work day, running to sporting events or playing with your children, Perfectly Simple is a nutritious, gluten-free, protein-packed snack under 200 calories that helps keep you going."

From Tobe Cohen, division vice president and general manager, Performance Nutrition, Abbott Nutrition:

"At ZonePerfect, we are committed to innovation and introducing new flavors each year that meet our consumers' ever-changing needs and taste preferences. This year, we asked consumers to help design the new bars. Given a variety of ingredients, consumers constructed their ideal nutrition bar with 10 grams of protein and flavors they enjoy. The result is Perfectly Simple and they're simply delicious."

See the article here:
Abbott Introduces New Limited Ingredient Nutrition Bar - Perfectly Simple™ by ZonePerfect®